Jung-Poppe Lea, Nicolaus Hagen Fabian, Roggenhofer Anna, Altenbuchner Anna, Dormann Harald, Pfistermeister Barbara, Maas Renke
Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
University Hospital Erlangen, 91054 Erlangen, Germany.
J Clin Med. 2022 Sep 1;11(17):5185. doi: 10.3390/jcm11175185.
Drug-related problems (DRP, defined as adverse drug events/reactions and medication errors) are a common threat for patient safety. With the aim to aid improved allocation of specialist resources and to improve detection and prevention of DRP, numerous predictive scoring tools have been proposed. The external validation and evidence for the transferability of these tools still faces limitations. However, the proposed scoring tools include partly overlapping sets of similar factors, which may allow a new approach to estimate the external usability and validity of individual risk factors. Therefore, we conducted this systematic review and analysis. We identified 14 key studies that assessed 844 candidate risk factors for inclusion into predictive scoring tools. After consolidation to account for overlapping terminology and variable definitions, we assessed each risk factor in the number of studies it was assessed, and, if it was found to be a significant predictor of DRP, whether it was included in a final scoring tool. The latter included intake of ≥ 8 drugs, drugs of the Anatomical Therapeutic Chemical (ATC) class N, ≥1 comorbidity, an estimated glomerular filtration rate (eGFR) <30 mL/min and age ≥60 years. The methodological approach and the individual risk factors presented in this review may provide a new starting point for improved risk assessment.
药物相关问题(DRP,定义为药物不良事件/反应和用药错误)是患者安全的常见威胁。为了有助于更好地分配专科资源,并改善药物相关问题的检测和预防,人们提出了许多预测评分工具。这些工具的外部验证和可转移性证据仍然存在局限性。然而,所提出的评分工具包含部分重叠的类似因素集,这可能为评估个体风险因素的外部可用性和有效性提供一种新方法。因此,我们进行了这项系统评价和分析。我们确定了14项关键研究,这些研究评估了纳入预测评分工具的844个候选风险因素。在合并以考虑重叠术语和变量定义后,我们评估了每个风险因素被评估的研究数量,以及如果它被发现是药物相关问题的显著预测因素,它是否被纳入最终评分工具。后者包括服用≥8种药物、解剖治疗化学(ATC)分类N类药物、≥1种合并症、估计肾小球滤过率(eGFR)<30 mL/min以及年龄≥60岁。本综述中提出的方法和个体风险因素可能为改进风险评估提供一个新的起点。